These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

74 related items for PubMed ID: 263185

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
    Hely MA, Morris JG, Reid WG, Trafficante R.
    Mov Disord; 2005 Feb; 20(2):190-9. PubMed ID: 15551331
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Early or late onset of L-dopa treatment in Parkinson disease?].
    von Kummer R, Schneevoigt K.
    Nervenarzt; 1986 Nov; 57(11):634-9. PubMed ID: 3808131
    [No Abstract] [Full Text] [Related]

  • 9. The relationship of the basic intellectual endowment of the Parkinson patient to the long-term effect of L-dopa.
    Boshes B, Arbit J, Blonsky ER, Dolkart M.
    Int J Neurol; 1979 Nov; 13(1-4):181-98. PubMed ID: 263183
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Tiapride in persistent dyskinesias following long-term L-dopa for parkinsonism].
    Arlazoroff A, Flechtir S, Goldexberg E, Bleicher Z, Barber Y.
    Harefuah; 1985 Mar 01; 108(5):227-9. PubMed ID: 4007677
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I, Serbănescu A, Tudorache B.
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982 Mar 01; 27(4):261-70. PubMed ID: 6222452
    [No Abstract] [Full Text] [Related]

  • 15. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy.
    Bouhaddi M, Vuillier F, Fortrat JO, Cappelle S, Henriet MT, Rumbach L, Regnard J.
    Auton Neurosci; 2004 Nov 30; 116(1-2):30-8. PubMed ID: 15556835
    [Abstract] [Full Text] [Related]

  • 16. Mental disorders in Parkinson's disease after treatment with L-DOPA.
    Rondot P, de Recondo J, Coignet A, Ziegler M.
    Adv Neurol; 1984 Nov 30; 40():259-69. PubMed ID: 6695602
    [No Abstract] [Full Text] [Related]

  • 17. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M, Nouzeilles MI, Arce GP, Leiguarda R.
    Mov Disord; 2002 Jul 30; 17(4):795-8. PubMed ID: 12210878
    [Abstract] [Full Text] [Related]

  • 18. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE.
    Arch Neurol; 2006 Feb 30; 63(2):205-9. PubMed ID: 16476808
    [Abstract] [Full Text] [Related]

  • 19. [Parkinson's disease and mental deterioration. Apropos of 30 cases].
    Mouren P, Poinso Y, Oppenheim G, Mouren A, Nguyen Quang N.
    Ann Med Psychol (Paris); 1983 Nov 30; 141(9):945-56. PubMed ID: 6666920
    [Abstract] [Full Text] [Related]

  • 20. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
    Caraceni T, Giovannini P, Girotti F, Parati E, Pederzoli M, Scigliano G.
    Ital J Neurol Sci; 1981 Dec 30; 2(4):337-42. PubMed ID: 7333824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.